Pharmaceutical Strategy Series presents....
Licensing & Partnering Congress
November 18-19, 2004
Cambridge, MA

                                     REGISTER BY OCTOBER 15th & SAVE UP TO $200! 

Corporate Sponsor:

Hear
Presentations from:





Download Brochure              Register Now!   

  Models to Evaluate the ROI of New
       Technologies

 Can Licensing Strategies Alter the High
      Rate of Failure for New Chemical Entities?

 Symbiosis of Large Pharma and Biotech:
      Getting the Interactions Right Through
      to Due Diligence
 
 Complementing Internal R&D with External
      Innovation

 Strategies to Protect Intellectual Property
      During Negotiations

DON'T MISS!

2004 Emerging Company Partnering Forum
November 18, 2004

4  3DM, Inc.
4  Dynogen Pharmaceuticals, Inc.
4  Faust Pharmaceuticals
4  Genodive
4  Gloucester Pharmaceuticals, Inc.		 4  Innovadigm Oncology
4  Molecular Therapeutics, Inc
4  Quintessence Biosciences, Inc.
4  Reify Corporation
4  TransTech Pharma Inc 

 Expert Critique Panel

-  Gregory Bell, Ph.D., M.B.A., Vice President, Pharmaceutical Practice,
   Charles River Associates

-  Robert Gould, Vice President, Licensing & External Research, 
   Merck Research Labs,

-  Lisa Gray, Managing Partner, Phoenix IP Ventures (former Director at GSK Ventures)

-  Michael Lytton, J.D., M.Sc., General Partner, Oxford Bioscience Partners

Download Brochure              Register Now!         

Or for more information, visit:  www.healthtech.com/2004/lic

 

 

This email has been circulated by BioPortfolio Ltd on behalf of Cambridge Healthtech Institute Inc. As a registered user of the BioPortfolio web sites, you were selected to receive this message in the genuine belief that it would be of interest to you.

Subscriber information:
To unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com WITH NO SUBJECT.  The system will automatically remove your email address from the list based on your email address.  If your email has changed please email peter.barfoot@bioportfolio.com with a list of your email address and we will manually unsubscribe for you.  Thank you for your understanding.

To subscribe for the BioPortfolio Bulletin in HTML, email:
bioportfolio-subscribe-request@peach.ease.lsoft.com

Disclaimer:
BioPortfolio Limited and its agents used their best efforts in collecting and preparing the information published herein. However, BioPortfolio does not assume, and hereby disclaims, any and all liability for any loss or damage caused by errors, whether such errors resulted from negligence, accident, or other causes. All rights reserved. ©2004 BioPortfolio Limited

BioPortfolio is the essential web resource for scientists, executives, investors, the public and the patient with an interest in who, what, where, when and why biotechnology will impact on our lives. We have created proprietary databases and search engines that will support your business and private interests in the most exiting technology of the 21st Century. BioPortfolio provides 14 Channels: www.bioportfolio.com/